Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BST-2227 LAI
- Development stage
- Unknown
- Lead developer
- Guangzhou Bosto Controlled-Release Pharmaceutical
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
BST-2227 LAI (also known as B2227) is a long-acting, extended-release subcutaneous injectable suspension of cariprazine, an atypical antipsychotic. Developed by Bostal Pharma (Bosto Controlled-Release Pharmaceutical) using its proprietary drug delivery platforms, BST-2227 LAI is designed for monthly (1M) and bimonthly (2M) administration to improve patient adherence and provide sustained therapeutic levels. Cariprazine acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. BST-2227 LAI is currently in clinical development for the treatment of schizophrenia, bipolar I disorder, major depressive disorder, and agitation associated with Alzheimer's dementia.
- Other names
- cariprazine extended-release injectable suspensioncariprazine LAIcariprazine long-acting injectable
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on BST-2227 LAI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BST-2227 LAI.